AI-native drug-discovery company launched with over $1 billion in initial funding. Led by CEO Marc Tessier-Lavigne (former Genentech chief scientific officer) and co-founded by protein-design pioneer David Baker, combining generative models with wet-lab drug development.
Based on public sources. If accuracy is important, verify details using the links or references.
For corrections, updates, or requests to remove information, contact us.
